Navigation Links
Circassia's Ragweed Allergy Therapy Achieves Positive Phase II Clinical Results
Date:3/8/2012

OXFORD, England, March 8, 2012 /PRNewswire/ --

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ragweed allergy therapy has achieved positive results in a key phase II clinical trial.  In the study, patients with more severe symptoms achieved a significantly greater improvement following treatment with the ToleroMune® T-cell vaccine than those on placebo (p≤0.05).  The results were presented at the 2012 Annual Meeting of the American Academy of Allergy, Asthma and Immunology*.  

"The results of this key phase II study are highly encouraging, because they show our ToleroMune ragweed allergy vaccine can reduce patients' symptoms after just a short course of treatment and, most importantly, offers the greatest improvement to those who can benefit most," said Steve Harris, Circassia's CEO. "We have now achieved successful phase II results with four of our allergy T-cell vaccines, which validate our scientific approach and give us the confidence to progress our lead programmes into the final phase of development."

Circassia's latest phase II study was designed to assess the T-cell vaccine's efficacy and tolerability and to identify the optimal treatment regime.  The trial was conducted in Canada in 275 ragweed allergy patients.  During the randomised, double-blind, placebo-controlled trial, volunteers received one of four regimens of ToleroMune treatment over a three-month period.  Patients were exposed to ragweed allergens in a validated exposure chamber, and investigators compared their nasal and ocular symptoms against the pre-treatment baseline.  The results show that the T-cell vaccine's optimal regimen substantially reduced patients' symptoms, achieving a 97% greater reduction than placebo (p≤0.05) in subjects who had a moderate level of symptoms at baseline.  The treatment was safe and well tolerated in all groups.
'/>"/>

SOURCE Circassia Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
2. Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists
3. AllergEase LLC Launches All-Natural Lozenges for Seasonal Allergy Sufferers
4. SRI International Awarded Contract Worth Up to $100M From National Institute of Allergy and Infectious Diseases
5. Planet Biopharmaceuticals, Inc. Divests Assets of Allergy Control Products, Inc.
6. Perrigo Company to Attend the 2011 Annual Meeting of the American College of Allergy, Asthma & Immunology
7. Jubilant HollisterStier Allergy Launches Allergy Industry Insights Educational Webinar Series
8. Allegra® and Survivor Winner Danni Boatwright Want to Hear About Your "Allergy Adventures"
9. Allergy Technologies LLC Provides Over $100,000 in a Research Grant to The Ohio State University for the Study of Bed Bugs
10. Food Allergies Common among Children and Linked to Environmental Allergies and Asthma Later in Life, Suggests Largest-Ever National Allergy Study
11. Cobalis Corp. Launches National Television Commercials for PreHistin® Allergy Defense Formula
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... PITTSBURGH, April 2, 2012 Cohera Medical, a ... and sealants, announced today that its lead product, ... 2012 Medical Design Excellence Awards in the General ... The Medical Design Excellence Awards is the medical ...
... Healthcare, India,s leading provider of integrated healthcare services ... (NASDAQ: MASI ) jointly announce a ... access to Masimo,s full line of the most technologically ... solutions. As part of the new ...
Cached Medicine Technology:TissuGlu® Surgical Adhesive Named 2012 Medical Design Excellence Awards Finalist 2TissuGlu® Surgical Adhesive Named 2012 Medical Design Excellence Awards Finalist 3Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 2Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 3Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 4Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 5Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 6Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 7Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 8
(Date:4/24/2014)... 24, 2014 ,Take me out to the ballgame, ... kale chips. The more likely culprits include French fries, ... Unfortunately for children who play youth baseball, eating unhealthy ... weight problems, according to researchers at Wake Forest Baptist ... edition of Childhood Obesity , found that high-calorie ...
(Date:4/24/2014)... and irrelevant, could offer an alternative to heart transplants ... Furtado, and her team from the Australian Regenerative Medicine ... fibroblast is a close relative to a cardiomyocyte, the ... research published today in Circulation Research , Dr ... due to their genetic program, and will aid in ...
(Date:4/24/2014)... to give than to receive at least if you,re ... , The study found that 15- and 16-year-olds who find ... family members, are less likely to become depressed than those ... the money for themselves. , The researchers detail their findings ... . , The study focused on the ventral striatum, a ...
(Date:4/24/2014)... National Science Foundation has awarded LSU Health Sciences ... (REU) Site grant in the amount of $295,635. ... from diverse social and educational backgrounds, underrepresented in ... The project will provide students with training ... It will be led by Principal Investigator ...
(Date:4/23/2014)... frozen stool from healthy, unrelated donors was safe ... diarrhea caused by Clostridium difficile , according ... Clinical Infectious Diseases and available online. Known ... effective whether given via a colonoscope or a ... make this promising treatment more readily available to ...
Breaking Medicine News(10 mins):Health News:Take the bat, leave the candy 2Health News:Boring cells could hold the key to heart disease 2Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2
... obtained promising results in the development of a male ... almost 45 years after Schering developed the female contraceptive ... of an implanted hormonal capsule and an injection given ... by a slightly-built 53-year-old woman, Professor Ursula-Friederike Habenicht, who ...
... from a small group of patients can provide an ... by private health practitioners and their office practice, according ... Internal Medicine. ,Highly consistent and reliable data ... according to the present study in which approximately 13,000 ...
... and 250,000 early-stage glaucoma patients risk blindness due to lack ... Royal National Institute for the Blind (RNIB).// In an attempt ... Eyes' has been launched in the UK. ,Apart ... suffer from some form of visual impairment in the UK. ...
... put to sleep in separate beds to reduce the risk ... deaths as a consequence of parents sleeping together// with ... recent years according to a report, published in the Lancet. ... and those that sleep on their side or front face ...
... which were found to be an effective anti-depressant is ... researchers are not sure about the mechanism of serotonin ... Professor Gerard Aherm and team from Georgetown University Medical ... which has been found to be an effective antidepressant ...
... Medical School researchers have reason to cheer. ,A ... at the location. ,A gene responsible for a ... an incurable degenerative brain disease affecting movement and coordination. ... that it is caused by mutations in the protein, ...
Cached Medicine News:Health News:Male Contraceptive Pill Being Developed By Berlin Pharmaceutical 2Health News:Ataxia: a problematic disease's gene deciphered 2
... Oxygen flowmeter with a Lexan®inner calibrated flow ... and manufacturing defects. A wide range of ... Also available with all popular inlet connections, ... double unit configurations. Our extra large knob ...
... Med TruFlow™ Oxygen flowmeter with a Lexan®inner ... covering calibration and manufacturing defects. A wide ... most needs. Also available with all popular ... take-off and double unit configurations. Our extra ...
... with a Lexan®inner calibrated flow tube has ... defects. A wide range of configurations are ... with all popular inlet connections, a 50 ... configurations. Our extra large knob coupled with ...
... adults, the entire series of time-tested Timeter® ... the needs of care providers and patients ... accuracy. You can see it in the ... performance, year after year. Every Timeter® Classic ...
Medicine Products: